Google to Invest in Regenerative Medicine

While the US government prints money to shore up failing and broken business models which no one likes but are considered simply too big (not too important or significant or even useful) to fail, Google is making money and investing it in start ups who expect nothing less than to create "disruptive, even world-changing technologies".

No suggestion here that GOOG is being altruistic, just that this is the way the new entrepreneur and investor class thinks. Opportunity and money are to be found in technologies that improve the way we live, work, play, eat, and think... and perhaps even improve the world.

To Google Ventures this has already meant wind farms, carbon emission reduction systems, green vehicles, and medical cures. To former Microsoft chief scientist Nathan Myhrvold and his high-level think tank, Intellectual Ventures, this means creating TerraPower - a company intending to revolutionize the nuclear power by developing reactors run on waste uranium - and also actively looking at regenerative medicine technologies.

Having formed the fund a little over a year ago, Google is only now starting to make a splash with the fund. Officially the fund has no specific industry focus saying on the Google Ventures website FAQ:

We are interested in a wide range of industries, including (but not limited to) consumer Internet, software, hardware, clean-tech, biotech, health care and others. First and foremost, we're looking for entrepreneurs who are tackling problems in creative and innovative ways, with the potential for significant financial return.

Unofficially and yet not so quietly, Google has named a few broad areas of interest. An article in Monday's New York Times quoted Google Ventures' managing partner, Bill Maris as saying that while they were not going to name particular investment themes, a few broad ares of interest include:

regenerative medicine, bioinformatics, cloud storage, companies that use large data sets, online monetization and mobile.

There it is. Regenerative medicine right there front and center.

In typical Google tradition, Maris, who looks all of 30 years old on the website, has a successfull and multidisciplinary track record. He was involved in founding Web hosting pioneer Burlee.com (now part of Web.com), where he built much of the key computing, network and technological infrastructure.Prior to that, Bill was a biotechnology and healthcare portfolio manager for Stockholm, Sweden-based Investor AB. Bill’s background also includes research at the Duke University Medical Center, Department of Neurobiology.

Google Ventures is said to be aiming at investing about $100 million a year. Any portion of that for regenerative medicine is more than welcome.

While traditional VC money remains reticent to back RM in any signifant way, Google's move confirms a trend we've been seeing and talking about at the Cell Therapy Group for the past 12 months or so. The multinational lifescience, biopharmaceutical, and healthcare companies along with strategic investors all now have regenerative medicine on their radar. They are all quietly and not-so quietly developing internal and external regenerative medicine strategies.

Please join us in welcoming regenerative medicine to the radar screen. It's bound to be an exciting ride ahead.

Take It Outside!

Just Five Minutes of Exercise Outdoors Boosts Mental Health, Researchers Say

In a bad mood? Improve it by going outside!

Here in New York and all around the country, summer is in the air.  It may say “May” on the calendar, but the weather sure doesn’t know that, as this week’s temperatures in New York City are headed for the 70s and 80s!

I hope it’s as nice where you are as it is here.  And if it is, instead of going to the gym after work to exercise today, head outside…even if it’s for just five minutes.  Because according to a new study on the mental health effects of exercising outside, the great outdoors can heighten your mood and your self-esteem.

Researchers from the University of Essex discovered this after reviewing the health habits of over 1,200 people from 12 separate studies.  Among the information collected from these men and women of all ages was their state of mental health (i.e. were they diagnosed with any kind of mental health disorder and cognitive dysfunction) and the kind of activities they did outside, such as walking, bicycling, gardening or horseback riding.

All of the individuals who exercised regularly showed improvements in their mental health, but those who saw the most significant improvement were those who performed what the researchers call “green exercises.”  Green exercises are any of the aforementioned exercises performed outside.  Other green exercises include farming, walking, gardening, fishing or boating.

“We believe that there would be a large potential benefit to individuals, society, and to the costs of the health service if all groups of people were to self-medicate more with green exercise,” said Jo Barton in a statement.  Barton co-authored the study with her colleague, Jules Pretty.

Their complete findings can be found in the journal Environmental Science & Technology.

Oh, and if you’re someone who loves the ocean, then you’re going to love this:  the biggest mental health effects were found among those who live near the water, like the ocean, a river or lake.

So, it seems, the closer you are to blue, the less likely you are to get “blue.”

As with many studies, this probably confirms the obvious.  But this research is illuminating nonetheless because up to now, no one really knew just how long it took to be outside to reap the mental health benefits.  And according to the researchers, it takes as little as five minutes.

So you know what that means?  No more excuses.  No more saying, “I can’t go outside for a walk because I don’t have any time on my lunch break.” Everybody has at least five minutes they can spend outdoors to walk.

Now, ideally, you’ll be exercising for longer than five minutes, but as I always say, some exercise is better than no exercise.  And that’s every bit as true for the mind as it is for the body.

Sources:
newsmaxhealth.com
news.bbc.co.uk

Discuss this post in Frank Mangano’s forum!

What to Do About the Fragility of Human Stem Cells

From the SENS Foundation: "Progress toward the goal of tissue rejuvenation via stem cells and tissue engineering ("RepleniSENS") is badly hampered by the surprising fragility of human embryonic stem cells (hESC) relative to mouse ESC (mESC). Unlike their murine counterparts, hESC undergo extensive cell death following enzymatic single-cell dissociation; as a result, researchers are forced to rely on laborious mechanical microdissection, or on narrowly-control enzymatic dissociation that ensures that hESC remain above a minimum cluster size. These requirements make their expansion extremely tedious and inefficient. The reasons for the intolerance of hESC to full dissociation - and the development of means to ameliorate it - are therefore of considerable biomedical as well as scientific interest. This month, researchers [report] that they have at once apparently provided the detailed molecular basis for this frustrating anomaly, and its abrogation using either modified culture protocols or either of two small molecules. ... Injected into an area that already enjoys a high level of government and industry investment, these tools bring us closer to realizing the promise of cell therapies and tissue engineering for the treatment of a range of age-related and traumatic diseases and disorders, as well as for the rejuvenation of aging tissues."

View the Article Under Discussion: http://www.sens.org/node/763

Read More Longevity Meme Commentary: http://www.longevitymeme.org/news/

An Example of Alcor's Work

Accelerating Future notes an example of Alcor's work in cryonics provision. We only tend to hear about the times when unusual obstructions crop up, and so it's worth a reminder that Alcor's staff and volunteers regularly make the difficult organization of a cryosuspension look routine: "This past month, Alcor was faced with three members who were admitted to hospice with end-stage conditions. On back-to-back days, two of our members were cryopreserved while the third member's condition has temporarily improved. Through careful planning, we were able to have two members admitted into the same Hospice of the Valley facility, literally across the hall from each other. This allowed Alcor's Arizona team to carefully monitor both members' conditions simultaneously, 24 hours a day. Having three team members and Alcor's Rescue Vehicle on site, we were able to provide immediate stabilization and cool down procedures and exceptionally quick transfer from time of pronouncement to Alcor's surgery suite in 40 minutes and 32 minutes, respectively. These cases were very important as they tested numerous benchmarks of Alcor's abilities ... The real benefit of all of our preparations, training and planning is to our members, who reportedly received excellent perfusions."

View the Article Under Discussion: http://www.acceleratingfuture.com/michael/blog/2010/05/alcors-93rd-and-94th-patients-cryopreserved-back-to-back/

Read More Longevity Meme Commentary: http://www.longevitymeme.org/news/

An Example of Alcor’s Work

Accelerating Future notes an example of Alcor's work in cryonics provision. We only tend to hear about the times when unusual obstructions crop up, and so it's worth a reminder that Alcor's staff and volunteers regularly make the difficult organization of a cryosuspension look routine: "This past month, Alcor was faced with three members who were admitted to hospice with end-stage conditions. On back-to-back days, two of our members were cryopreserved while the third member's condition has temporarily improved. Through careful planning, we were able to have two members admitted into the same Hospice of the Valley facility, literally across the hall from each other. This allowed Alcor's Arizona team to carefully monitor both members' conditions simultaneously, 24 hours a day. Having three team members and Alcor's Rescue Vehicle on site, we were able to provide immediate stabilization and cool down procedures and exceptionally quick transfer from time of pronouncement to Alcor's surgery suite in 40 minutes and 32 minutes, respectively. These cases were very important as they tested numerous benchmarks of Alcor's abilities ... The real benefit of all of our preparations, training and planning is to our members, who reportedly received excellent perfusions."

View the Article Under Discussion: http://www.acceleratingfuture.com/michael/blog/2010/05/alcors-93rd-and-94th-patients-cryopreserved-back-to-back/

Read More Longevity Meme Commentary: http://www.longevitymeme.org/news/

The Limits of Therapy

From the SENS Foundation: "To date, the dominant therapeutic strategy for both specific age-related diseases and (to the extent that it has been contemplated) the degenerative biological aging process itself, has been based on altering metabolic pathways. Biomedical research has centered on the detailed understanding of pathways seen to be contributing to disease etiology or pathogenesis, and the identification of putatively dysfunctional components hormones, receptors, enzymes, cytokines, etc), which are then targeted for manipulation by small molecules or other means in hopes of normalizing function and thereby alleviating symptoms or slowing progression of pathology. ... there is a critical flaw in the unconsciously-drawn analogy between its use in the development of therapies to manage specific diseases, and its potential for the treatment of the degenerative aging process. Unlike most non-communicative diseases, degenerative aging is not the result of the dysfunction of metabolic pathways, but of the the undesirable long-term side-effects of their normative biochemistry. Put another way: biological aging is the pathological result of perfectly-functioning, [healthy] metabolic processes. ... Thus, transposing the conventional drug-development pathway onto the aging process necessarily entails interfering with the normal metabolism - and doing on an indefinite basis, from the day that a 'patient' first begins therapy until his or her death. But of course, those same pathways evolved to ensure survival and fitness, and their existence and the normal mode of regulation are the very basis of ordinary health and function. We interfere with the intrinsic operation of such pathways at our peril."

View the Article Under Discussion: http://www.sens.org/node/747

Read More Longevity Meme Commentary: http://www.longevitymeme.org/news/

Thoughts on Rejuvenation and Alzheimer's Vaccines

A detailed examination of recent progress from the SENS Foundation: "Recent years have seen both substantial progress, and significant frustration, in the preferred regenerative engineering approach to the treatment and prevention of Alzheimer's disease (AD), and the eventual regeneration of genuinely youthful cognitive function: immunotherapeutic clearance of beta-amyloid (AmyloSENS). ... results appear to many to commend an earlier window of opportunity for intervention, before concomitant [damage] and neuronal losses have made the removal of beta-amyloid alone insufficient for cognitive rescue. Early intervention might also maximize the therapeutic window for vaccination, preventing the burden of beta-amyloid neuropathology from ever reaching levels so high as to interact with other forms of aging damage in already frail and immunosenescent people." Present work on immune therapies for clearing unwanted biochemical junk from the body looks promising - there is every sign that today's advances will broaden into a general technology platform for this purpose. Researchers will be able to develop therapies that can be applied incrementally throughout life to remove the age-related gunk like beta-amyloid before it rises to dangerous levels.

View the Article Under Discussion: http://www.sens.org/node/757

Read More Longevity Meme Commentary: http://www.longevitymeme.org/news/

Thoughts on Rejuvenation and Alzheimer’s Vaccines

A detailed examination of recent progress from the SENS Foundation: "Recent years have seen both substantial progress, and significant frustration, in the preferred regenerative engineering approach to the treatment and prevention of Alzheimer's disease (AD), and the eventual regeneration of genuinely youthful cognitive function: immunotherapeutic clearance of beta-amyloid (AmyloSENS). ... results appear to many to commend an earlier window of opportunity for intervention, before concomitant [damage] and neuronal losses have made the removal of beta-amyloid alone insufficient for cognitive rescue. Early intervention might also maximize the therapeutic window for vaccination, preventing the burden of beta-amyloid neuropathology from ever reaching levels so high as to interact with other forms of aging damage in already frail and immunosenescent people." Present work on immune therapies for clearing unwanted biochemical junk from the body looks promising - there is every sign that today's advances will broaden into a general technology platform for this purpose. Researchers will be able to develop therapies that can be applied incrementally throughout life to remove the age-related gunk like beta-amyloid before it rises to dangerous levels.

View the Article Under Discussion: http://www.sens.org/node/757

Read More Longevity Meme Commentary: http://www.longevitymeme.org/news/

Health care reform bill dooms America to Pharma-dominated sickness and suffering

Today the medical mafia struck another devastating blow to the health and freedom of all Americans. With the support of an inarguably corrupt Congress that has simply abandoned the real needs of the American people, the sick-care industry has locked in a high-profit scheme of disease and monopoly-priced pharmaceuticals in a nation that can ill afford either one.

And this Pharma-funded betrayal, it turns out, was led by the Democrats. Passed on a 219-212 vote that was only accomplished thanks to closed-door, last-minute secret meetings among the last holdouts, this new legislation puts America under the stranglehold of the medical mafia while doing absolutely nothing to address real health care reform. There is no mention in the bill Read more...

Youtharia for Anti-Aging & Longevity

CSC news links 2010-05-01

For links to recent news items, visit these [Twitter] or [FriendFeed] pages. Examples of two news items that have received attention:?

More about presentations at AACR10

Five presentations at the 101th annual meeting of the American Association of Cancer Research were highlighted a news release from Geron Corporation (dated March 3, 2010). One presentation that had an explicit focus on CSC was this poster:

Imetelstat, a telomerase inhibitor in phase I trials in solid tumor and hematological malignancies, has broad activity against multiple types of cancer stem cells [Presentation Abstract].

Also mentioned in the news release was an oral presentation by Jerry W Shay, given as part of the Major Symposium entitled: Role of Telomeres and Telomerase in Chromosomal Stability and Disease [Session Detail]. The presentation was:

Role of telomerase in normal and neoplastic stem cells [Presentation Abstract].

Another poster about the telomerase inhibitor imetelstat (GRN163L) was:

Sensitivity and resistance of non-small cell lung cancer to the telomerase inhibitor imetelstat [Presentation Abstract].

Comments: A search of the ClinicalTrials.gov database for GRN163L revealed 6 trials. Four were ongoing, but not recruiting participants. Two were still recruiting: 1) Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies; 2) A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer.

An analogous search for imetelstat yielded the same 6 trials. All 6 trials have been sponsored by Geron Corporation.

Thoughts on Transhumanism From Humanity+ UK

An attendee at the Humanity+ UK 2010 conference offers thoughts on transhumanist goals: "The convergence of current technologies such as nanotechnology, biotechnology, information technology and cognitive science (NBIC) and future technologies such as artificial intelligence, mind uploading, cryonics, and simulated reality, is truly inspirational. ... I think we all have a vested interest in Aubrey de Grey's idea that aging is simply a disease, and a curable one at that. His plan is to identify all the components that cause human tissue to age, and design remedies for each of them through his approach called SENS (Strategies for Engineered Negligible Senescence). Once we can extend human life spans by thirty years, we're well on our way to immortality. Aubrey de Grey claims that the first human being to live a thousand years has probably already been born. From the way he talks, the biggest challenge in the race against mortality is funding! So I highly encourage those of you with means and an interest to donate to the SENS Foundation. ... Another fascinating speaker was David Pearce, advocating the abolition of suffering throughout the living world. ... He argues that as we develop these technologies, it is both our moral and hedonistic imperative to rid all sentient beings of pain."

View the Article Under Discussion: http://beforeitsnews.com/news/38084/Transhumanism_and_the_Future_of_the_Human_Race.html

Read More Longevity Meme Commentary: http://www.longevitymeme.org/news/

Looking to the Future of Personalized Medicine

Sequencing our own DNA and cross-referencing the results against the best of present scientific knowledge will soon be cheap and routine. This is an example of the sort of incremental progress in medical technology that is increasing human life expectancy year after year: a little more prevention here, a little better insight into how to cure there. From ScienceDaily: "For the first time, researchers have used a healthy person's complete genome sequence to predict his risk for dozens of diseases and how he will respond to several common medications. The risk analysis [also] incorporates more-traditional information such as a patient's age and gender and other clinical measurements. The resulting, easy-to-use, cumulative risk report will likely catapult the use of such data out of the lab and into the waiting room of average physicians within the next decade, say the scientists. ... The $1,000 genome is coming fast. The challenge lies in knowing what to do with all that information. We've focused on establishing priorities that will be most helpful when a patient and a physician are sitting together looking at the computer screen. ... Information like this will enable doctors to deliver personalized health care like never before. Patients at risk for certain diseases will be able to receive closer monitoring and more frequent testing, while those who are at lower risk will be spared unnecessary tests. This will have important economic benefits as well, because it improves the efficiency of medicine."

View the Article Under Discussion: http://www.sciencedaily.com/releases/2010/04/100429204658.htm

Read More Longevity Meme Commentary: http://www.longevitymeme.org/news/

On Attacking Cancer Stem Cells

This EurekAlert! release looks at some of the challenges facing the increasing number of research groups who are attempting to destroy cancer stem cells: "Many of the colon cancer cells that form tumors can be killed by genetically short-circuiting the cells' ability to absorb a key nutrient, a new study has found. While the findings are encouraging, the test tube study using human colon cancer cells also illustrates the difficulty of defeating these cells, known as cancer stem cells (CSCs). ... It is becoming more evident that only a small number of cells in the tumor are capable of forming the tumor, namely the cancer stem cell. So the new strategy is to eliminate the cancer stem cells and thus lower the recurrence of cancer. ... Because CSCs have properties similar to normal stem cells, we have to find a way to attack them while keeping the adult stem cells alive. ... To do that, the research team inactivated a receptor that is found in increased amounts in colon cancer cells: the insulin-like growth factor receptor (IGF-1R). The colon cancer CSCs seem to need a fair amount of IGF to live, more than other cells, and they can't function without the IGF receptor. ... Working with human colon cancer cells, the researchers manipulated the cellular genetics using small interfering RNA (siRNA) to prevent the synthesis of IGF-1R. In this way, they reduced the number of IGF receptors by half, and reduced the number of CSCs by 35%."

View the Article Under Discussion: http://www.eurekalert.org/pub_releases/2010-04/foas-ras042210.php

Read More Longevity Meme Commentary: http://www.longevitymeme.org/news/

On the Pope's Opposition to Engineered Longevity

From TechNewsWorld: "During his homily this Easter, Pope Benedict argued that medical science, in trying to defeat death, is leading humanity toward likely condemnation. It's a position at odds with the value of life, one that the Church will likely revise years from now, replaying the institution's embarrassment over censoring Galileo. ... If scientists are successful in finding techniques to rebuild cartilage, repair organs, and cure cancer, people will indeed be living longer - but they will also be healthier, more energetic and youthful. Health-extension, when it happens, will allow people to live longer, better. Consider that 60-year-olds today are not in the same shape as their counterparts were in the 1800s or 1900s. As humans discovered how to take better care of themselves, through improved nutrition, the use of antibiotics and other techniques, 'chronological age' became less synonymous with 'biological age.' That is, many of today's 60-year-olds act and feel much younger than one might expect. The average human life expectancy today is close to 80 years but in 1850, it was 43 years, and in 1900 it was 48 years. One can imagine someone in 1850 arguing that doubling life expectancy would be terrible, because innovation might be at risk and there would be more old people around. But would anyone today say they are sorry that science made it possible to live longer and healthier lives?"

View the Article Under Discussion: http://www.technewsworld.com/story/Galileo-20-Here-Comes-Another-Apology-69876.html

Read More Longevity Meme Commentary: http://www.longevitymeme.org/news/

On the Pope’s Opposition to Engineered Longevity

From TechNewsWorld: "During his homily this Easter, Pope Benedict argued that medical science, in trying to defeat death, is leading humanity toward likely condemnation. It's a position at odds with the value of life, one that the Church will likely revise years from now, replaying the institution's embarrassment over censoring Galileo. ... If scientists are successful in finding techniques to rebuild cartilage, repair organs, and cure cancer, people will indeed be living longer - but they will also be healthier, more energetic and youthful. Health-extension, when it happens, will allow people to live longer, better. Consider that 60-year-olds today are not in the same shape as their counterparts were in the 1800s or 1900s. As humans discovered how to take better care of themselves, through improved nutrition, the use of antibiotics and other techniques, 'chronological age' became less synonymous with 'biological age.' That is, many of today's 60-year-olds act and feel much younger than one might expect. The average human life expectancy today is close to 80 years but in 1850, it was 43 years, and in 1900 it was 48 years. One can imagine someone in 1850 arguing that doubling life expectancy would be terrible, because innovation might be at risk and there would be more old people around. But would anyone today say they are sorry that science made it possible to live longer and healthier lives?"

View the Article Under Discussion: http://www.technewsworld.com/story/Galileo-20-Here-Comes-Another-Apology-69876.html

Read More Longevity Meme Commentary: http://www.longevitymeme.org/news/

Latest Cell Therapy Approval by FDA. Dendreon's Provenge.

It has been a long-time coming. It has been hyped and scoffed, bet against and hoped for, but now none of that matters. It's here. Dendreon has brought Provenge to market. Here, in the word's of the FDA...

FDA NEWS RELEASE

For Immediate Release: April 29, 2010

FDA Approves a Cellular Immunotherapy for Men with Advanced Prostate Cancer

The U.S. Food and Drug Administration today approved Provenge (sipuleucel-T), a new therapy for certain men with advanced prostate cancer that uses their own immune system to fight the disease.

Provenge is indicated for the treatment of asymptomatic or minimally symptomatic prostate cancer that has spread to other parts of the body and is resistant to standard hormone treatment.

Prostate cancer is the second most common type of cancer among men in the United States, behind skin cancer, and usually occurs in older men. In 2009, an estimated 192,000 new cases of prostate cancer were diagnosed and about 27,000 men died from the disease, according to the National Cancer Institute.

“The availability of Provenge provides a new treatment option for men with advanced prostate cancer, who currently have limited effective therapies available,” said Karen Midthun, M.D., acting director of the FDA’s Center for Biologics Evaluation and Research.

Provenge is an autologous cellular immunotherapy, designed to stimulate a patient’s own immune system to respond against the cancer. Each dose of Provenge is manufactured by obtaining a patient’s immune cells from the blood, using a machine in a process known as leukapheresis. To enhance their response against the cancer, the immune cells are then exposed to a protein that is found in most prostate cancers, linked to an immune stimulating substance. After this process, the patient’s own cells are returned to the patient to treat the prostate cancer. Provenge is administered intravenously in a three-dose schedule given at about two-week intervals.

The effectiveness of Provenge was studied in 512 patients with metastatic hormone treatment refractory prostate cancer in a randomized, double-blind, placebo-controlled, multicenter trial, which showed an increase in overall survival of 4.1 months. The median survival for patients receiving Provenge treatments was 25.8 months, as compared to 21.7 months for those who did not receive the treatment.

Almost all of the patients who received Provenge had some type of adverse reaction. Common adverse reactions reported included chills, fatigue, fever, back pain, nausea, joint ache and headache. The majority of adverse reactions were mild or moderate in severity. Serious adverse reactions, reported in approximately one quarter of the patients receiving Provenge, included some acute infusion reactions and stroke. Cerebrovascular events, including hemorrhagic and ischemic strokes, were observed in 3.5 percent of patients in the Provenge group compared with 2.6 percent of patients in the control group.

Provenge is manufactured by Seattle-based Dendreon Corp.

Latest Cell Therapy Approval by FDA. Dendreon’s Provenge.

It has been a long-time coming. It has been hyped and scoffed, bet against and hoped for, but now none of that matters. It's here. Dendreon has brought Provenge to market. Here, in the word's of the FDA...

FDA NEWS RELEASE

For Immediate Release: April 29, 2010

FDA Approves a Cellular Immunotherapy for Men with Advanced Prostate Cancer

The U.S. Food and Drug Administration today approved Provenge (sipuleucel-T), a new therapy for certain men with advanced prostate cancer that uses their own immune system to fight the disease.

Provenge is indicated for the treatment of asymptomatic or minimally symptomatic prostate cancer that has spread to other parts of the body and is resistant to standard hormone treatment.

Prostate cancer is the second most common type of cancer among men in the United States, behind skin cancer, and usually occurs in older men. In 2009, an estimated 192,000 new cases of prostate cancer were diagnosed and about 27,000 men died from the disease, according to the National Cancer Institute.

“The availability of Provenge provides a new treatment option for men with advanced prostate cancer, who currently have limited effective therapies available,” said Karen Midthun, M.D., acting director of the FDA’s Center for Biologics Evaluation and Research.

Provenge is an autologous cellular immunotherapy, designed to stimulate a patient’s own immune system to respond against the cancer. Each dose of Provenge is manufactured by obtaining a patient’s immune cells from the blood, using a machine in a process known as leukapheresis. To enhance their response against the cancer, the immune cells are then exposed to a protein that is found in most prostate cancers, linked to an immune stimulating substance. After this process, the patient’s own cells are returned to the patient to treat the prostate cancer. Provenge is administered intravenously in a three-dose schedule given at about two-week intervals.

The effectiveness of Provenge was studied in 512 patients with metastatic hormone treatment refractory prostate cancer in a randomized, double-blind, placebo-controlled, multicenter trial, which showed an increase in overall survival of 4.1 months. The median survival for patients receiving Provenge treatments was 25.8 months, as compared to 21.7 months for those who did not receive the treatment.

Almost all of the patients who received Provenge had some type of adverse reaction. Common adverse reactions reported included chills, fatigue, fever, back pain, nausea, joint ache and headache. The majority of adverse reactions were mild or moderate in severity. Serious adverse reactions, reported in approximately one quarter of the patients receiving Provenge, included some acute infusion reactions and stroke. Cerebrovascular events, including hemorrhagic and ischemic strokes, were observed in 3.5 percent of patients in the Provenge group compared with 2.6 percent of patients in the control group.

Provenge is manufactured by Seattle-based Dendreon Corp.

An Interview With the Departing Sirtris CEO

An interesting article: "In what turned out to be his final official engagement as CEO of Sirtris Pharmaceuticals, Christoph Westphal offered some key lessons in how to build a successful biotech company ... It's pretty amazing ... in the last 20 years, we've gone from zero understanding of the genes that play a role in aging to a pretty clear understanding that IGF1 plays a role, MTOR, the Sirtuins play a role, there's 10-15 genes play a role. Many of those are going to be druggable targets. Will Sirtris be successful? I don't know. It's still going to be very risky. But I'll be shocked if there are not drugs in the next 10-15 years that target genes that control aging. ... Westphal did not shirk from addressing the ongoing controversy surrounding the physiological activity of some Sirtris compounds. ... There's a debate in the academic world. We don't know the specific molecular mechanism of why you need a specific substrate on the in vitro screen to find Sirt1 activators. ... It's a numbers game and it's gotten harder with the FDA ... People are spending less on pharma R&D and more on consumer health care and trying to diversify into developing countries and away from Europe and the United States. Fewer drugs are getting approved, revenues are going down, margins are going to go down."

View the Article Under Discussion: http://www.bio-itworld.com/news/04/26/10/Christoph-Westphal-on-aging-pharmageddon.html

Read More Longevity Meme Commentary: http://www.longevitymeme.org/news/